Ajay Rai was hospitalised after fainting due to Hyponatremia, highlighting the dangers of low sodium and the importance of ...

Axsome Therapeutics (NASDAQ:AXSM) announced that the U.S. Food and Drug Administration has approved Auvelity for the ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 ...

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...

Mineralys Therapeutics, Inc. ( MLYS) Bank of America Global Healthcare Conference 2026 May 12, 2026 12:20 PM EDT From Mineralys, I have here with me today, Jon Congleton. Jon, thanks for joining us. I ...

European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, May 01, 2026 (GLOBE ...

Hydration is vital for people managing both type 2 diabetes and chronic kidney disease, but the right amount of water isn’t one-size-fits-all. Needs change with disease stage, other health conditions, ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...

ADMA Biologics Announces FDA Approval To Expand The Label For ASCENIVTM To Include Pediatric Immune Compromised Patients Two Years Of Age And Older. RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 ...

Cirrhotic ascites is driven by proximal tubular sodium reabsorption, mainly via NHE3. Due to spatial coupling of NHE3 and SGLT2, SGLT2 inhibitors ...